MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
The TDR Three Takeaways:
Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has enter
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced
MariMed Sets Up Shop In Illinois Town Known For Guinness World Record-Holding Attractions
MariMed Inc. (OTC: MRMD) retail footprint has once again expanded, as the company officially unveiled an adult-use Thrive dispensary in Casey, Illinois
‘Star Studded’ Benzinga Cannabis Capital Conference Arrives At A Time Where Critical Reform In On The Horizon
A lot of news action could happen in cannabis this week, between actions in Washington DC, and Benzinga’s Cannabis Capital Conference taking place September 27 through 28. In this episode of the Trade To Black podcast, we are sitting down with Elliot Lane, the Host & Corporate Partnerships Manager at Benzinga.
MindMed’s Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders,
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III clinical trial initiation today.
COMPASS’ Securities Purchase Agreement Is Big News
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the…
Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
On this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviews Awakn Life Sciences Corp. (OTC: AWKNF) CEO Anthony Tennyson, as his company moves closer towards a Phase III clinical trial explor